Table 1.
Systems | PS | Tumor‐related factors | Liver function | AFP | Prior Tx | LiverDxb | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
Size | Nodes | PVT | Extenta | CP | Alb | Bili | |||||
TNM7 | ✖ | ✔ | ✔ | ✔ | ✖ | ✖ | ✖ | ✖ | ✖ | ✖ | ✖ |
BCLC | ✔ | ✔ | ✖ | ✔ | ✖ | ✔ | ✖ | ✔ | ✖ | ✖ | ✖ |
CLIP | ✖ | ✔ | ✖ | ✔ | ✔ | ✔ | ✖ | ✔ | ✔ | ✖ | ✖ |
Okuda | ✖ | ✔ | ✖ | ✖ | ✔ | ✖ | ✔ | ✔ | ✖ | ✖ | ✖ |
ALBI | ✖ | ✖ | ✖ | ✖ | ✖ | ✖ | ✔ | ✔ | ✖ | ✖ | ✖ |
AFP, alpha‐fetoprotein; Alb, albumin; ALBI, albumin–bilirubin grade; BCLC, Barcelona Clinic Liver Cancer; Bili, bilirubin; CLIP, Cancer of Liver Italian Program; CP, Child–Pugh classification; HCC, hepatocellular carcinoma; PS, performance status; PVT, portal vein thrombosis; TNM7, TNM staging seventh edition; Tx, treatment.
Extent of primary tumor compared to liver area (greater or less than 50%).
Etiology of liver disease.